Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 5, 2007, Pages 561-574

  Chang, Yong S ^a   Adnane, Jalila ^a   Trail, Pamela A ^a   Levy, Joan ^a   Henderson, Arris ^a   Xue, Dahai ^a   Bortolon, Elizabeth ^a   Ichetovkin, Marina ^a   Chen, Charles ^a   McNabola, Angela ^a   Wilkie, Dean ^a   Carter, Christopher A ^a   Taylor, Ian C A ^a   Lynch, Mark ^a   Wilhelm, Scott ^a  

^a BAYER CORPORATION   (United States)

Author keywords

Angiogenesis; Multi kinase inhibitor; Renal cell carcinoma; Sorafenib; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; FLUORESCEIN ISOTHIOCYANATE; HISTONE H3; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 3; PIMONIDAZOLE; PLATELET DERIVED GROWTH FACTOR; SMOOTH MUSCLE ACTIN; SORAFENIB; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; HYPOXIA; IMMUNOHISTOCHEMISTRY; KIDNEY CAPSULE; KIDNEY CARCINOMA; NICK END LABELING; NONHUMAN; OUTPATIENT DEPARTMENT; PERICYTE; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; STAINING; TISSUE SECTION; TUMOR BLEEDING; TUMOR VASCULARIZATION; TUMOR VOLUME; VASCULARIZATION; XENOGRAFT;

ACTINS; ADENOCARCINOMA, CLEAR CELL; ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; ANTIGENS, CD31; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CAPILLARIES; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KIDNEY NEOPLASMS; MICE; MICE, NUDE; PYRIDINES; REGIONAL BLOOD FLOW; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33847118123     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0393-4     Document Type: Article

References (35)

1. Alavi A, Hood JD, Frausto R, Stupack DG, Cheresh DA (2003) Role of Raf in vascular protection from distinct apoptotic stimuli. Science 301:94-96
2. Amato RJ (2005) Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16:7-15
3. An J, Fisher M, Rettig MB (2005) VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-kappaB-dependent mechanism. Oncogene 24:1563-1570
4. Benjamin LE, Hemo I, Keshet E (1998) A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125:1591-1598
5. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E (1999) Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 103:159-165
6. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287-1295
7. Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M (2006) BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 98:326-334
8. Clark JW, Eder JP, Ryan D, Lathia C, Lenz HJ (2005) Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 11:5472-5480
9. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T (2005) Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev:CD001425
10. Ebbinghaus SW, Gordon MS (2004) Renal cell carcinoma: rationale and development of therapeutic inhibitors of angiogenesis. Hematol Oncol Clin North Am 18:1143-1159, ix-x
11. Escudier B, Szczylik C, Eisin T, Stadler W, Schwartz B, Shan M, Bukowski R (2005) Randomized phase III trial of the multi-kinase inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). Eur. J. Cancer Supplements 3:226
12. Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967-974
13. Figlin RA (1999) Renal cell carcinoma: management of advanced disease. J Urol 161:381-6; discussion 386-387
14. Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS (2006) Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 66:3639-3648
15. Godley PA, Taylor M (2001) Renal cell carcinoma. Curr Opin Oncol 13:199-203
16. Gore ME, Escudier B (2006) Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma. Oncology (Williston Park) 20:19-24
17. Holash J, Wiegand SJ, Yancopoulos GD (1999) New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 18:5356-5362
18. Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404-2407
19. Hurwitz H (2004) Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4(Suppl 2):S62-S68
20. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342
21. Jain RK (2003) Molecular regulation of vessel maturation. Nat Med 9:685-693
22. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
23. Jain RK, Duda DG, Clark JW, Loeffler JS (2006) Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3:24-40
24. Josko J, Mazurek M (2004) Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 10:RA89-RA98
25. Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R (2004) B-RAF is a therapeutic target in melanoma. Oncogene 23:6292-6298
26. Kim JH, Jung CW, Cho YH, Lee J, Lee SH, Kim HY, Park J, Park JO, Kim K, Kim WS, Park YS, Im YH, Kang WK, Park K (2005) Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma. Oncol Rep 13:859-864
27. Mancuso A, Sternberg CN (2005) New treatments for metastatic kidney cancer. Can J Urol 12 Suppl 1: 66-70; discussion 105
28. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ, Metz EM (2000) Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18:1928-1935
29. Na X, Wu G, Ryan CK, Schoen SR, di'Santagnese PA, Messing EM (2003) Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. J Urol 170:588-592
30. Salvatore G, De Falco V, Salerno P, Nappi TC, Pepe S, Troncone G, Carlomagno F, Melillo RM, Wilhelm SM, Santoro M (2006) BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 12:1623-1629
31. Shaheen PE, Bukowski RM (2005) Emerging drugs for renal cell carcinoma. Expert Opin Emerg Drugs 10:773-795
32. Sharma A, Trivedi NR, Zimmerman MA, Tuveson DA, Smith CD, Robertson GP (2005) Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65:2412-2421
33. Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M (2006) Renal cancer cells lacking hypoxia inducible factor (HIF)-1{alpha} expression maintain vascular endothelial growth factor expression through HIF-2{alpha}. Carcinogenesis
34. Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL (2002) Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. Cancer Res 62:2957-2961
35. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099-7109